745048-07-1

Basic information

• Product Name: 1-BOC-4-(4-AMINOBUTYL)PIPERAZINE
• Synonyms: BUTTPARK 90\06-07;1-BOC-4-(4-AMINOBUTYL)PIPERAZINE;4-(4-Amino-butyl)-piperazine-1-carboxylicacidtert-butylester;tert-butyl 4-(4-aminobutyl)piperazine-1-carboxylate;1-Piperazinecarboxylicacid, 4-(4-aminobutyl)-, 1,1-dimethylethyl ester
• CAS NO: 745048-07-1
• Molecular Formula: C₁₃H₂₇N₃O₂
• Molecular Weight: 257.37
• Product Categories: pharmacetical
• Mol File: 745048-07-1.mol

Chemical Properties

• Boiling Point: 353.8°C at 760 mmHg
• Flash Point: 167.7°C
• Appearance: /
• Density: 1.029g/cm³
• Vapor Pressure: 3.51E-05mmHg at 25°C
• Refractive Index: 1.491
• CAS DataBase Reference: 1-BOC-4-(4-AMINOBUTYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-(4-AMINOBUTYL)PIPERAZINE(745048-07-1)
• EPA Substance Registry System: 1-BOC-4-(4-AMINOBUTYL)PIPERAZINE(745048-07-1)

Safety Data

• Hazardous Substances Data: 745048-07-1(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
1-BOC-4-(4-AMINOBUTYL)PIPERAZINE is used as a key intermediate in the synthesis of complex organic molecules, particularly in the development of new pharmaceutical compounds. Its presence in the structure aids in the formation of desired chemical bonds and reactions, facilitating the creation of novel molecules with potential applications in various fields.
Used in Pharmaceutical Research:
1-BOC-4-(4-AMINOBUTYL)PIPERAZINE is used as a building block in the design and synthesis of new drugs. Its piperazine ring and BOC-protected amine group contribute to the compound's overall structure, which can be further modified to create drugs with specific therapeutic properties. 1-BOC-4-(4-AMINOBUTYL)PIPERAZINE is particularly valuable in the development of medications for various diseases and conditions.
Used in Peptide Synthesis:
1-BOC-4-(4-AMINOBUTYL)PIPERAZINE is used as a component in the synthesis of peptides. The BOC group protects the amine group during the peptide assembly process, allowing for the stepwise construction of peptide chains. Once the desired peptide sequence is achieved, the BOC group can be removed to reveal the free amine, enabling further modifications or the formation of peptide bonds.
Used in Drug Delivery Systems:
1-BOC-4-(4-AMINOBUTYL)PIPERAZINE can be incorporated into drug delivery systems to improve the solubility, stability, and bioavailability of therapeutic agents. Its presence in the structure of drug carriers or conjugates can enhance the interaction with biological targets, leading to more effective drug delivery and therapeutic outcomes.

InChI:InChI=1/C13H27N3O2/c1-13(2,3)18-12(17)16-10-8-15(9-11-16)7-5-4-6-14/h4-11,14H2,1-3H3

Upstream product

• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 745048-06-0 4-[4-(1,3-dioxo-1,3-dihydroisoindol-2-yl)butyl]piperazine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1351412-06-0 tert-butyl 4-(4-(cyclohexylmethylsulfonamido)butyl)piperazine-1-carboxylate 
• 1351412-07-1 1-cyclohexyl-N-(4-(piperazin-1-yl)butyl)methanesulfonamide 
• 1351412-08-2 1-cyclohexyl-N-(4-(4-(6-nitropyridin-2-yl)piperazin-1-yl)butyl)methane-sulfonamide 

Relevant articles and documents

PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT)

The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below: Formula (I)

RADIOLABELED COMPOUNDS AND METHODS THEREOF

The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.

PYRIDINYL DERIVATIVES COMPRISING A CYANOGUANIDINE OR SQUARIC ACID MOIETY

The present application discloses compounds of the formula (I) wherein X = opt.subst. pyrid-3-yl or pyrid-4-yl; Q = opt.subst. Ci-6 alkylene or a single bond; Y is formula (i) wherein D is = N-CN, or formula (ii) B = is opt.subst. C1-6 alkylene; A = (formula) Z = -J-V, wherein J = -C(=0)-, -C(=O)-O, -S(=O)2-, -P(=O)(OR4)-, -C(=O)-NR4- and -C(=S)-NR4-, and V = opt.subst. C1-12-alkyl, opt.subst. C3-12-cycloalkyl, -[CH2CH2O]1-10-( opt.subst. C1-6-alkyl), opt.subst. C1-12- alkenyl, opt.subst. aryl, opt.subst. heterocyclyl, or opt.subst. heteroaryl; q = 0-2, and r = 0- 2; and pharmaceutically acceptable salts thereof, and prodrugs thereof. The application also discloses the compound for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT), e.g. inflammatory and tissue repair disorders; dermatosis; autoimmune diseases, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, ataxia telengiectasia.

Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor

Following a recent description of fluorescence resonance energy transfer between enhanced green fluorescent protein (EGFP)-fused human muscarinic M1 receptors and Bodipy-labeled pirenzepine, we synthesized seven fluorescent derivatives of this antagonist in order to further characterize ligand-receptor interactions. These compounds carry Bodipy [558/568], Rhodamine Red-X [560/580], or Fluorolink Cy3 [550/570] fluorophores connected to pirenzepine through various linkers. All molecules reversibly bind with high affinity to M1 receptors (radioligand and energy transfer binding experiments) provided that the linker contains more than six atoms. The energy transfer efficiency exhibits modest variations among ligands, indicating that the distance separating EGFP from the fluorophores remains almost constant. This also supports the notion that the fluorophores may bind to the receptor protein. Kinetic analyses reveal that the dissociation of two Bodipy derivatives (10 or 12 atom long linkers) is sensitive to the presence of the allosteric modulator brucine, while that of all other molecules (15-24 atom long linkers) is not. The data favor the idea that these analogues might interact with both the acetylcholine and the brucine binding domains.